Hyderabad: The collaborative landscape of international pharmaceutical oversight reached a new milestone on May 5, 2026, as the Drugs Control Administration (DCA) of Telangana hosted the Second Regulatory Forum with the United States Food and Drug Administration (FDA).
Held at the DCA Headquarters in Vengal Rao Nagar in Hyderabad, the forum underscored a shared commitment to strengthening global supply chains and ensuring the safety of medical products exported from India’s ‘Life Sciences Capital’.
The high-level meeting was attended by a distinguished US FDA delegation led by Greg Smith, country director, along with regulatory specialists Lisa Flores and Rafeeq Habeeb, and senior technical advisor Dhruv Shah. Their presence highlighted the strategic importance of Telangana, which currently houses over 214 US FDA-approved manufacturing sites, making the state a critical pillar in the healthcare ecosystem of the United States.
Serving as a robust knowledge-sharing platform, the forum focused on the exchange of best practices in the inspection of medicinal products. US FDA investigators led several technical sessions focused on advanced Good Manufacturing Practices (GMP) concepts. These sessions provided local regulators with a deeper understanding of international audit expectations and the evolving complexities of global pharmaceutical manufacturing.
In a proactive display of regional progress, DCA officers presented their latest regulatory initiatives and inspection trends. A significant portion of the presentation was dedicated to the implementation of the revised Schedule M and the nuances of conducting inspections in sterile manufacturing facilities. These updates demonstrated Telangana’s efforts to modernize its domestic standards in alignment with global benchmarks.
The discussions also served to refine the ‘Observed Inspection’ model, a unique arrangement where Telangana DCA inspectors participate as official observers in US FDA-led audits. This hands-on collaboration, which has already seen state officers attend 13 previous inspections, is designed to build local capacity and ensure that field-level enforcement is both rigorous and transparent.
Central to the deliberations was the advancement of public health through risk-based oversight. Both agencies explored strategies to combat emerging challenges such as antimicrobial resistance (AMR) and the contamination of liquid orals. By synchronizing their inspection approaches, the US FDA and DCA aim to prevent the distribution of sub-standard or spurious medicines before they reach the consumer market.
The forum concluded with a reinforced pledge to continue this strategic partnership, which remains one of the few such formalized arrangements between the US FDA and an Indian state. By significantly enhancing the technical expertise of DCA inspectors, the meeting ensured that the pharmaceutical output from Telangana continues to meet the highest standards of safety, quality, and efficacy for patients worldwide.
